+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis C - Pipeline Insight, 2021

  • ID: 5306353
  • Clinical Trials
  • July 2021
  • Region: Global
  • 100 Pages
  • DelveInsight

FEATURED COMPANIES

  • Adaptimmune
  • AllaChem
  • Atea Pharmaceuticals
  • Dekk-Tec
  • GeneCure Biotechnologies
  • HEC Pharm
This Hepatitis C - Pipeline Insight, 2021 provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hepatitis C pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Hepatitis C Understanding


Hepatitis C: Overview


Hepatitis C is a liver infection caused by the hepatitis C virus. Hepatitis C can range from a mild illness lasting a few weeks to a serious, long-term illness. The hepatitis C virus (HCV) spreads through contaminated blood. The hepatitis C virus is a blood borne virus, the most common modes of infection are through exposure to small quantities of blood. This may happen through injection drug use, unsafe injection practices, unsafe health care, transfusion of unscreened blood and blood products, and sexual practices that lead to exposure to blood. Hepatitis C is often described as “acute,” meaning a new infection, or “chronic,” meaning long-term infection. Chronic hepatitis C can be a serious disease resulting in long-term health problems, including liver damage, liver failure, cirrhosis, liver cancer, and even death. Symptoms may include fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, grey-colored faeces, joint pain and jaundice (yellowing of skin and the whites of the eyes). Treatments for hepatitis C includes antivirals, like medications called direct-acting antivirals (DAAs) work to fully remove the hepatitis C virus from the body while helping prevent liver damage.

Hepatitis C - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis C pipeline landscape is provided which includes the disease overview and Hepatitis C treatment guidelines. The assessment part of the report embraces, in depth Hepatitis C commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis C collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis C R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis C.

Hepatitis C Emerging Drugs Chapters


This segment of the Hepatitis C report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis C Emerging Drugs


TG-2349: Dongguan HEC TaiGen Biopharmaceuticals

TG-2349 (Furaprevir) is a HCV protease inhibitor. It is a novel direct acting antivirals for the all-oral treatment of chronic hepatitis C virus (HCV) infection. The drug has completed Phase III clinical evaluation in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected patients.

SH229: Nanjing Sanhome Pharmaceutical

SH229 is a NS5B inhibitor that is being developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic hepatitis C virus infection. The drug is currently in Phase II/III clinical studies combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets for the treatment of hepatitis C virus infection.

Hepatitis C: Therapeutic Assessment


This segment of the report provides insights about the different Hepatitis C drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Hepatitis C


There are approx. 20+ key companies which are developing the therapies for Hepatitis C. The companies which have their Hepatitis C drug candidates in the most advanced stage, i.e. Phase III include, Dongguan HEC TaiGen Biopharmaceuticals.

Phases


This report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Hepatitis C pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis C: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis C therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis C drugs.

Hepatitis C Report Insights

  • Hepatitis C Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Hepatitis C Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Hepatitis C drugs?
  • How many Hepatitis C drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis C?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatitis C therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hepatitis C and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Dongguan HEC TaiGen Biopharmaceuticals
  • Nanjing Sanhome Pharmaceutical
  • PharmaEssentia
  • HEC Pharm
  • Atea Pharmaceuticals
  • AllaChem
  • HepC
  • Sunshine Lake Pharma
  • GeneCure Biotechnologies
  • Therapure Innovations
  • Adaptimmune
  • Orgenesis
  • Dekk-Tec

Key Products

  • TG-2349
  • SH229
  • Ropeginterferonum alfa-2b
  • Yimitasvir
  • AT 527
  • AV4025
  • HC-001
  • HEC 74647PA
  • Prophylactic HCV vaccine
  • TBI-301

Research program: T-cell therapies

Research programme: antiviral vaccines
  • IFN alpha CS(g)
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adaptimmune
  • AllaChem
  • Atea Pharmaceuticals
  • Dekk-Tec
  • GeneCure Biotechnologies
  • HEC Pharm

IntroductionExecutive Summary
Hepatitis C: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)
  • Comparative Analysis

TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

AT 527: Atea Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

HEC 74647PA: Sunshine Lake Pharma
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical and Discovery Stage Products
  • Comparative Analysis

Prophylactic HCV vaccine: GeneCure Biotechnologies
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Hepatitis C Key CompaniesHepatitis C Key ProductsHepatitis C- Unmet NeedsHepatitis C- Market Drivers and BarriersHepatitis C- Future Perspectives and ConclusionHepatitis C Analyst ViewsHepatitis C Key CompaniesAppendix
List of Tables
Table 1 Total Products for Hepatitis C
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Hepatitis C
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Dongguan HEC TaiGen Biopharmaceuticals
  • Nanjing Sanhome Pharmaceutical
  • PharmaEssentia
  • HEC Pharm
  • Atea Pharmaceuticals
  • AllaChem
  • HepC
  • Sunshine Lake Pharma
  • GeneCure Biotechnologies
  • Therapure Innovations
  • Adaptimmune
  • Orgenesis
  • Dekk-Tec
Note: Product cover images may vary from those shown